Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues

May 31, 2022

Lab technician injecting a substance into a vial in a labratory.

Guidance Document

Center for Drug Evaluation and Research

This guidance describes the Food and Drug Administration’s (FDA’s) current recommendations regarding the overall development program to establish the effectiveness and safety of gonadotropin-releasing hormone (GnRH) analogues for treating advanced prostate cancer.

The recommendations in section III.C., Registrational Trial Considerations, apply to drug product development programs for GnRH analogues in advanced prostate cancer for all dosage forms and routes of administration (e.g., tablets, capsules, injectable suspensions, injectable emulsions, subcutaneous implants). Other sections apply only to extended-release injectable dosage forms.

Download the Final Guidance Document

Final Level 1 Guidance

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.

TAGS:

January 27, 2016

FDA's CDER Announces New & Revised Draft Guidances it Plans to Publish in 2016

On Friday, January 22, FDA’s Center for Drug Evaluation and Research (CDER) published its 2016 guidance agenda. The guidance agenda is published on an annual basis and announces the draft guidances...

February 3, 2017

FDA Releases CDER’s 2017 Guidance Agenda

Last month, FDA’s Center for Drug Evaluation and Research (CDER) released its annual guidance agenda, announcing the new and revised draft guidances that the Center plans to publish during the 2017...

February 3, 2016

FDA’s CBER Announces Invitation to Participate in the Regulatory Site Visit Training Program

On February 2, 2016, the FDA’s Center for Biologics Evaluation and Research (CBER) published its annual invitation for biologics facilities to participate in the Regulatory Site Visit Training...